News
SILO
1.750
0.00%
0.000
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 1d ago
Weekly Report: what happened at SILO last week (0914-0918)?
Weekly Report · 6d ago
Biotech Stocks In Focus - IMCC +245%, XRTX +12%, SILO, BFRI
NASDAQ · 09/18 19:27
Silo Pharma receives U.S. patent allowance for SPC-15 PTSD treatment
TipRanks · 09/18 13:10
Silo Pharma Receives U.S. Patent Office Notice Of Allowance For Application Covering SPC-15, Its Novel Intranasal Therapeutic Targeting Post-Traumatic Stress Disorder
Benzinga · 09/18 12:52
Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio
Barchart · 09/18 07:50
Weekly Report: what happened at SILO last week (0907-0911)?
Weekly Report · 09/14 09:39
Silo Pharma To Highlight SPC-15 Nose-To-Brain Technology At 2026 Nasal Innovation Forum
NASDAQ · 09/09 15:28
Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum
Barchart · 09/09 08:15
Weekly Report: what happened at SILO last week (0831-0904)?
Weekly Report · 09/07 09:36
Weekly Report: what happened at SILO last week (0824-0828)?
Weekly Report · 08/31 09:40
Weekly Report: what happened at SILO last week (0817-0821)?
Weekly Report · 08/24 09:40
Psychedelic: Enveric, Helus, Bright Minds report earnings results
TipRanks · 08/20 15:30
Silo Pharma Acquires Digital Assets via Stock Issuance
TipRanks · 08/19 21:51
Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting On August 18, 2026; Issues 165,000 Shares As Consideration For Asset Purchase
Benzinga · 08/19 21:21
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 08/19 12:07
Silo Strengthens IP Portfolio With Canadian Patent Allowance For PTSD Drug Candidate; Stock Down
NASDAQ · 08/19 05:34
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 08/18 21:06
Silo Pharma receives notice of allowance from CIPO for PTSD treatment
TipRanks · 08/18 20:20
Silo Pharma Says Canadian Intellectual Property Office Issues Notice Of Allowance For Patent Application Covering SPC-15, Intranasal 5-HT4 Receptor Agonist Targeting PTSD And Other Stress-Induced Psychiatric Disorders
Benzinga · 08/18 20:16
More
Webull provides a variety of real-time SILO stock news. You can receive the latest news about Silo Pharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About SILO
Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.